Clinical Trial Update: Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy [Phase 2]

View source ↗

Summary

Phase 2 trial of WT1 peptide vaccine in high-risk hematologic malignancies (myelodysplastic syndrome, acute myeloid leukemia, and chronic myeloid leukemia) comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• WT1 peptide vaccine (WT1 peptide vaccine)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML) | Phase 2 | Status: COMPLETED | Results posted: 2014-07-08